Regeneron Pharmaceuticals (REGN)
NASDAQ:REGN
Want to see REGN full AI Analyst Report?
Bpx-601
Prostate Cancer
Phase I
Not Yet Recruiting
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Apr 14, 2026
―
Regn7508, Apixaban
Venous Thromboembolism (Vte)
Phase III
Recruiting
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Mar 05, 2026
―
Regn9933, Regn7508
Atrial Fibrillation (Af)
Phase III
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Feb 18, 2026
―
Regn13335
Pulmonary Arterial Hypertension (Pah)
Phase II
Recruiting
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Jan 02, 2026
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Regeneron Pharmaceuticals (REGN) have in its pipeline
REGN is currently developing the following drugs: Bpx-601, Regn7508, Apixaban, Regn9933, Regn7508. These drug candidates are in various stages of clinical development as the company works toward FDA approval.